细胞因子-超抗原融合蛋白实际上是代替现有技术的抗体的，也具有靶向作用，是区别于抗体的新的可期待的药物。
The superantigen fusion protein cell factor is actually a substitute for the antigen in the prior art, has a targeting function and is a new prospective medicament different from the antigen.
细胞因子-超抗原融合蛋白对于实体肿瘤有着很明显的杀伤作用。
The cell factor-superantigen fusion protein has an obvious killing effect on the solid tumor.
应用推荐